Microcapsules comprising a peptide having cell receptor binding ability and cosmetic compositions comprising the same

Abstract

Disclosed in the present specification are a peptide having cell receptor binding ability, a microcapsule linked to the peptide, and a cosmetic composition containing the same. The peptide of an embodiment of the present invention has excellent selective binding ability to a target, and the microcapsule has excellent physicochemical stability. Therefore, the cosmetic composition containing the microcapsule linked to the peptide has excellent delivery efficiency to target cells of an effective ingredient contained in the capsule, and excellent skin condition improvement effect.

Description

Technical Field

[0001] This specification discloses peptides having cell receptor binding energy, microcapsules linked to the aforementioned peptides, and cosmetic compositions containing the same. Background Technology

[0002] Microcapsules are a fundamental technology used in various fields such as pharmaceuticals, coatings, electronics, and cosmetics, especially as the best tool for maintaining the initial efficacy of active ingredients, and have attracted much attention in the pharmaceutical and cosmetic fields (Journal of controlled release, 58, 9, 1999).

[0003] However, cosmetic compositions containing microcapsules, as discovered to date, do not provide significantly improved effects when applied to the human body compared to cosmetic compositions that do not use microcapsules.

[0004] Accordingly, the technology for delivering microcapsules to target cells has recently been developed based on the principles of drug delivery systems. However, to date, it has been found that due to the molecular instability of microcapsules and issues with their binding affinity to target cells, satisfactory results cannot be achieved.

[0005] Existing technical documents

[0006] (Patent Document 1) KR 10-1051557B1 Summary of the Invention

[0007] Technical issues

[0008] In one embodiment, the object of the present invention is to provide a peptide with excellent binding affinity to target cells.

[0009] In one embodiment, the object of the present invention is to deliver the active ingredient correctly and stably to target cells.

[0010] In one embodiment, the object of the present invention is to provide a cosmetic composition in which the delivery of active ingredients to the skin is improved.

[0011] Solution to the problem

[0012] In one embodiment, the present invention provides a peptide having cell receptor binding energy, wherein the peptide is a peptide comprising any one of the sequences 1 to 3.

[0013] In one embodiment, the present invention provides microcapsules with the above-described peptides linked to a surface.

[0014] Furthermore, in one embodiment, the present invention provides a cosmetic composition comprising the aforementioned microcapsules.

[0015] The effects of the invention

[0016] The peptide of one embodiment of the present invention exhibits excellent selective binding affinity to its target. Furthermore, the microcapsule of one embodiment of the present invention demonstrates excellent physicochemical stability. Therefore, in cosmetic compositions comprising microcapsules bound to the aforementioned peptide, the delivery efficiency of the active ingredient contained within the capsule to target cells is excellent, resulting in excellent skin condition improvement. Attached Figure Description

[0017] Figure 1 shows the results confirming the binding force with the target (target cells) of the capsule of the present invention. Figure 1a Capsule 1 Figure 1b Capsule 2, Figure 1c : Capsule 3).

[0018] Figure 2 shows the processing of capsule 1 of the present invention, indicating collagen 1 ( Figure 2a ), Collagen 2 ( Figure 2b ) and elastin ( Figure 2c A diagram showing the changes in expression.

[0019] Figure 3 A figure showing the effect of using ampoules containing the capsules of the present invention to confirm the improvement of crow's feet.

[0020] Figure 4 shows the binding inhibition energy of α-MSH when the capsule (capsule 2) of the present invention is processed. Figure 4a ) and melanin synthesis inhibitory energy ( Figure 4b (The image is missing.)

[0021] Figure 5 A graph showing the whitening effect after using a toner containing the capsules of this invention.

[0022] Figure 6 shows the confirmation of keratin 1 ( ) during the processing of the capsule (capsule 3) of the present invention. Figure 6a ), keratin 5 ( Figure 6b Figure 6C shows the expression changes of filaggrin and filaggrin.

[0023] Figure 7 A graph showing the effect of using a nourishing cream containing the capsules of the present invention to confirm the improvement of the skin barrier (peridermal density, skin thickness).

[0024] Figure 8 This diagram illustrates a microcapsule on a multilayer structure formed from lipids, in which an excess of the hydrophilic physiologically active substance of the present invention is stabilized.

[0025] Figure 9 This is a diagram illustrating a microcapsule containing peptides.

[0026] Figure 10 A photograph of a concentrated composition sample manufactured using the intelligent packaging manufacturing technology of the present invention. Detailed Implementation

[0027] The present invention will now be described in detail.

[0028] In one embodiment, the present invention is a peptide having cell receptor binding energy, wherein the peptide is a peptide comprising any one of the sequences in sequence numbers 1 to 3.

[0029] In this specification, cell receptor binding energy refers to the ability to bind to receptors formed on cells.

[0030] The amino acid sequences of the peptides with sequence numbers 1 to 3 are shown in Table 1 below.

[0031] Table 1

[0032] Serial Number amino acid sequence 1 Ala-Lys-Ser-Thr 2 Glu-Gly-His-Lys-Ile-Phe-Pro-Ser-Trp-Tyr 3 Ala-Asp-Gly-Ser-Pro

[0033] In Table 1 above, Ala means alanine, Asp means aspartic acid, Glu means glutamic acid, Gly means glycine, His means histidine, Ile means isoleucine, Lys means lysine, Phe means phenylalanine, Pro means proline, Ser means serine, Trp means tryptophan, Tyr means tyrosine, and Thr means threonine.

[0034] In one embodiment, the cells targeting the peptide may include melanocytes, keratinocytes, or fibroblasts.

[0035] Furthermore, the aforementioned cell receptors may include fibroblast growth factor receptors, integrin receptors, or melanocortin receptors. Specifically, the aforementioned melanocortin receptor may be the melanocortin 1 receptor (MC1R).

[0036] In one instance, the peptide at sequence number 1 targets fibroblasts and can bind to the fibroblast growth factor receptor.

[0037] Furthermore, in one instance, the peptide at sequence number 2 targets melanocytes and can bind to the melanocortin receptor.

[0038] Furthermore, in one instance, the peptide of sequence number 3 targets keratinocytes and can bind to integrin receptors, particularly the β1 family of integrin receptors.

[0039] In one embodiment of the present invention, the above-mentioned peptides do not bind to cells other than the target cell or its receptor. Due to their excellent binding force, when the peptides are linked to other components, high delivery force to the target can be expected.

[0040] In one embodiment, the present invention comprises microcapsules on which the aforementioned peptides are attached. The peptides can be attached to the microcapsules by binding hydrophilic groups on the microcapsules, such as binding carboxyl groups to the N-terminus of the peptides; however, the attachment method is not limited and can be based on various methods known to those skilled in the art.

[0041] Microcapsules can contain a wide variety of polymers, including, but not limited to, polymers, heat-sensitive polymers, light-sensitive polymers, magnetic polymers, pH-sensitive polymers, salt-sensitive polymers, chemically sensitive polymers, high molecular weight electrolytes, polysaccharides, peptides, proteins and / or plastics. The polymers include, but are not limited to, substances such as poly(N-isopropylacrylamide) (PNIPAAm), poly(styrene sulfonate) (PSS), poly(acrylamine) (PAAm), poly(acrylic acid) (PAA), poly(ethyleneimine) (PEI), poly(diallylmethylammonium chloride) (PDADMAC), poly(pyrrole) (PPy), poly(vinylpyrrolidone) (PVPON), poly(vinylpyridine) (PVP), poly(methacrylic acid) (PMAA), poly(methyl methacrylate) (PMMA), polystyrene (PS), poly(tetrahydrofuran) (PTHF), poly(phthalaldehyde) (PTHF), poly(hexyl viologen) (PHV), poly(L-lysine) (PLL), polyvinyl alcohol (PVA), poly(L-arginine) (PARG), and poly(lactic-co-glycolic acid copolymer) (PLGA).

[0042] In one example, the capsule may be double-layered, in which case the outer layer may contain polyvinyl alcohol and the inner layer may contain poly(lactic acid-glycolic acid copolymer) (PLGA).

[0043] Furthermore, microcapsules may contain one or more substances in the outer layer of the capsule that can generate an effective neutral, negative, or positive charge. In some cases, the charge of the capsule may help prevent or promote particle aggregation or clustering.

[0044] In one embodiment, the peptides, based on the total cross-sectional area of ​​the microcapsules, can be distributed at a rate of 0.1–10 peptides / μm. 2 The density of the peptides is preferably 0.3–8 peptides / μm. 2 The most preferred value is 0.4–7 peptides / μm. 2Peptide density can be interpreted as the number of peptides present per unit surface area of ​​a microcapsule.

[0045] For example, the density of peptides on the microcapsules is less than 0.1 peptides / μm. 2 In the case of, or greater than 10 peptides / μm 2 In this case, it exhibits skin condition improvement effects similar to microcapsules that are not linked to peptides, and within the above density range, it has excellent binding force with target cells and delivery force of effective ingredients to target cells.

[0046] In one embodiment, the microcapsule further comprises an active ingredient encapsulated within the capsule. This active ingredient may include: amino acids; plant-derived proteins or their hydrolysates; and one or more of yeast ferments, their solutions, or their filtrates. Furthermore, the active ingredient encapsulated within the capsule may include various plant extracts and their fruit extracts. Specifically, the plant extracts may include daffodil bulb extract, summer snowflake bulb extract, etc., and the fruit extracts may include dragon fruit extract.

[0047] Furthermore, the aforementioned amino acids are not limited and may include arginine, alanine, glutamine, glycine, isoleucine, leucine, lysine, histidine, proline, tyrosine, serine, valine, phenylalanine, tryptophan, threonine, aspartic acid, etc.

[0048] In one instance, the plant-derived protein may include lupin protein, and the yeast may include Pichia pastoris. In another instance, the yeast ferment may be Pichia pastoris fermented dissolution filtrate.

[0049] In the above respects, plant-derived proteins or their hydrolysates and yeast ferments, their solutions or filters, can be contained in amounts ranging from 0.0001 to 30% by weight, based on the total weight of the active ingredients. When the amount is less than 0.0001% by weight, the effect is minimal; when it is greater than 30% by weight, stability problems such as discoloration and off-flavor may occur. The aforementioned plant-derived proteins or their hydrolysates; yeast ferments; and their solutions or filters, based on the total weight of the active ingredients, can preferably be contained in amounts ranging from 0.01 to 30% by weight, more preferably from 0.01 to 25% by weight.

[0050] The aforementioned amino acids may be contained in an amount of 0.00001 to 0.1% by weight, preferably 0.0001 to 0.1% by weight, more preferably 0.0001 to 0.05% by weight, and the aforementioned plant extracts or fruit extracts may be contained in an amount of 0.0001 to 30% by weight. The aforementioned plant extracts and fruit extracts may each be preferably contained in an amount of 0.001 to 20% by weight, and most preferably in an amount of 0.001 to 15% by weight.

[0051] When the content of amino acids is less than 0.00001% by weight, the efficacy is minimal; when it is greater than 0.1% by weight, there will be issues with the viscosity stability of the dosage form.

[0052] When the plant extracts and fruit extracts are less than 0.0001% by weight, the effect is minimal. When they are greater than 30% by weight, there may be problems with discoloration, change in taste, and viscosity stability of the dosage form.

[0053] When the ingredients listed above are contained within the above-mentioned content range, the best moisturizing, skin barrier strengthening, whitening, wrinkle improvement and skin elasticity improvement effects can be obtained.

[0054] In one embodiment, the present invention is a cosmetic composition comprising the above-described microcapsules. The composition may be for moisturizing, skin barrier strengthening, whitening, wrinkle improvement, or skin elasticity improvement.

[0055] In this specification, skin barrier strengthening may mean promoting the differentiation of keratinocytes, strengthening the outermost layer of the skin, and improving skin condition.

[0056] In one embodiment, the above composition can promote the synthesis of keratin 1, keratin 5, keratin 10, keratin 14, filaggrin, naphthalene, elastin, collagen, etc.

[0057] In one embodiment, the content of microcapsules in the above-mentioned cosmetic composition can be 0.0001 to 30% by weight, preferably 0.001 to 20% by weight, and most preferably 0.01 to 10% by weight.

[0058] When the content of microcapsules in a cosmetic composition is less than 0.0001% by weight, the effect is minimal. When it is greater than 30% by weight, the dispersibility of the capsules in the composition decreases, and the cosmetic composition loses its adhesiveness.

[0059] The present invention will now be described through manufacturing examples and embodiments. These manufacturing examples and embodiments are merely illustrative and should not be construed as limiting the scope of the invention to these examples.

[0060] [Manufacturing Example]

[0061] [Manufacturing Example 1] Manufacturing of Peptides

[0062] The peptides with sequence numbers 1 to 3 in Table 1 above were synthesized using an automated synthesizer (PeptrEx-R48, Peptron Corporation, Daejeon, South Korea) via the FMOC solid-phase method. The synthesized peptides were purified and analyzed using reverse-phase HPLC (Prominence LC-20AB, Shimadzu Corporation, Japan) on an RP column (Shiseido Capcell Pak), and identified using a mass analyzer (HP 1100 Series LC / MSD, Hewlett-Packard Corporation, Roseville, USA).

[0063] [Manufacturing Example 2] Manufacturing of Microcapsules

[0064] [Manufacturing Example 2-1] Manufacturing of peptide-free microcapsules

[0065] Lipid concentrate (ceramide, cholesterol, hydrogenated lecithin) was added to an additional dissolving tank and heated to 70°C to dissolve. Hydrophilic bioactive substance (panthenol, raffinose, nicotinamide, green tea water) was added to another additional dissolving tank and heated to 45°C to dissolve, for later use. The prepared lipid concentrate was then added to a dissolving tank containing a lipid stabilizer and stirred at 1500 rpm for 5 minutes while maintaining 50°C. The hydrophilic bioactive substance was then added, and the mixture was stirred at 1500 rpm for 5 minutes to homogenize, preparing a first concentrated phase from which excess hydrophilic active ingredients were massively homogenized. The first concentrated phase was then maintained at 50°C and stirred at a low speed of 500 rpm for 1 hour to fully hydrate it. Furthermore, at 50°C, the aforementioned hydrated first concentrated phase was fed into a high-pressure emulsifier and processed twice at a pressure of 9000 Pa. This allowed excess hydrophilic bioactive substances to be concentrated and encapsulated at nanoscale in the aqueous phase between the innermost aqueous phase and the lipid bilayer, forming the second concentrated phase. Then, at 28°C, the mixture was slowly stirred at 500 rpm in an agitator while being cooled and stabilized to produce unbound peptide microcapsules. The diameter of the produced microcapsules was approximately 0.2 micrometers.

[0066] [Manufacturing Example 2-2] Manufacturing of Peptide-Attached Microcapsules

[0067] The peptide from Manufacturing Example 1 was attached to the microcapsule manufactured in Manufacturing Example 2-1.

[0068] The N-terminus of the peptide was linked to the carboxyl group on the surface of the unbound microcapsules, thus attaching the peptide of Example 1 to the surface of the microcapsules. Specifically, the unbound microcapsules were resuspended in 2-(N-morpholino)ethanesulfonic acid (MES, pH 5.5) buffer and reacted with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) and N-hydroxysuccinimide (NHS) for approximately 1 hour. Afterward, the microcapsules were centrifuged at approximately 15,000 rpm for 1 hour to remove EDAC and NHS, activating the surface of the unbound microcapsules. Next, the microcapsules were suspended in approximately 100 ml of phosphate-buffered saline (PBS), and approximately 0.1 g of peptide SEQ ID NO. 1 was reacted with the microcapsules at room temperature. Unreacted peptides were then washed with PBS buffer. Peptides SEQ ID NO. 2 and 3 were also prepared using the same method, adjusting the reagent dosage to create peptide-linked microcapsules. The attachment of peptides to the microcapsules was confirmed by the Kaiser test using ninhydrin. Furthermore, the peptide density on the surface of the microcapsules was measured using a scanning electron microscope (JSM-7100F), showing approximately 2 peptide s / μm. 2 The density.

[0069] The microcapsule linked to the peptide of sequence number 1 is called capsule 1, the microcapsule linked to the peptide of sequence number 2 is called capsule 2, and the microcapsule linked to the peptide of sequence number 3 is called capsule 3.

[0070] [Manufacturing Example 3] Peptide density regulation on microcapsules

[0071] Microcapsules were manufactured in the same manner as in Example 2, and the peptide density of the microcapsule phase was adjusted by regulating the dosage of the peptide. Experimental groups were then divided according to the density as follows.

[0072] Table 2

[0073]

[0074] [Example]

[0075] [Example 1] Cytotoxicity test

[0076] B16 melanoma cells were treated with 1-3 capsules at 10 μM each to confirm cell viability. As a control group, cells were treated with kojic acid and arbutin. The results showed that cell viability remained almost unchanged when treated with the capsules of the present invention, thus confirming the absence of cytotoxicity.

[0077] [Example 2] Binding selectivity test with target cells

[0078] To determine whether capsules 1-3 bind to other cells besides the target cells, it was confirmed whether they bind to multiple cell types. The results showed that capsules 1-3 bind almost no to cells other than the target cells.

[0079] [Example 2-1] Capsule 1

[0080] The binding affinity of capsule 1 to cells was confirmed using fluorescence immunoassay and flow cytometry (FACS). The cells used included fibroblasts, keratinocytes, lymphocytes, monocytes, melanocytes, dendritic cells, and skin neurons. The results confirmed that capsule 1 bound to fibroblasts (the target cells) at approximately 75%, while the binding affinity to cells other than the target cells was significantly lower. Figure 1a ).

[0081] [Example 2-2] Capsule 2

[0082] Capsule 2 was also tested using the same method as in Example 2-1. The results confirmed that capsule 2 exhibited approximately 70% binding affinity to melanocytes, which are the target cells, while its binding affinity to other cells was significantly low. Figure 1b ).

[0083] [Examples 2-3] Capsules 3

[0084] Capsule 3 was also tested using the same method as in Examples 2-3. The results confirmed that capsule 3 exhibited a binding rate of approximately 85% with keratinocytes, the target cells, while its binding rate with other cells was significantly low. Figure 1c ).

[0085] [Example 3] Anti-aging effect of microcapsules linked to peptides (capsules 1-3)

[0086] [Example 3-1] Binding force between fibroblasts and capsules (comparing binding forces based on the presence or absence of peptides)

[0087] The binding affinity of microcapsules with peptide-linked surfaces to fibroblasts and the absorption capacity of active ingredients were compared between microcapsules without peptide-linked surfaces.

[0088] Capsule 1 was cultured with target cells at 4°C for 1 hour to delay the binding process. The binding affinity of microcapsules with and without peptide-linked peptides to fibroblasts was then measured. The binding affinity of capsule 1 to fibroblasts was approximately four times greater than that of the microcapsules without peptide-linked peptides.

[0089] [Example 3-2] Comparison of collagen and elastin generating capacity

[0090] Microcapsules with peptides attached to their surface were reacted with fibroblasts to observe the production of elastin and collagen.

[0091] When using capsules with unlinked peptides, collagen production is minimal. Conversely, when using capsules with linked peptides, collagen production of types 1 and 3 increases by approximately 1.7 times compared to capsules with unlinked peptides. Figure 2a , Figure 2b ).

[0092] In terms of elastin production, after 7 days following the capsule reaction, capsule 1, which was bound to a peptide, showed up to 9 times more elastin production than capsules without peptides. Figure 2c ).

[0093] [Example 3-3] Evaluation Test on Skin Wrinkle Improvement

[0094] Ampoules containing 30 wt% of capsule 1 were manufactured. Twenty-one women aged 35–65 years without skin diseases applied the ampoules evenly to their entire face twice daily for 28 days to assess the improvement in crow's feet. Results confirmed an approximately 10% improvement in crow's feet. Figure 3 ).

[0095] [Example 4] Whitening effect of microcapsules containing linker peptides (capsules 2-3)

[0096] [Example 4-1] Inhibitory effect of melanocyte-α-MSH binding

[0097] Microcapsules with peptide-linked surfaces (capsule 2) and microcapsules without peptide-linked surfaces were treated with 10 μM each, and the binding affinity between melanocytes and α-melanocyte-stimulating hormone (MSH) was measured. The results showed that using capsule 2 reduced the binding affinity between melanocytes and α-MSH by more than 95%. Figure 4a ).

[0098] [Example 4-2] Melanin Synthesis Inhibition Energy

[0099] Microcapsules with peptide-linked surfaces and microcapsules without peptide-linked surfaces were treated with 10 μM each, and the amount of melanin synthesized was compared. The results showed that when capsule 2 was used, the amount of melanin produced by melanocytes was significantly reduced. Figure 4b ).

[0100] [Example 4-3] Skin Whitening Effect Evaluation Test

[0101] Twenty-one women aged 35-55 without skin diseases participated in a study. A toner containing 15% Capsule 2 was applied evenly to the entire face twice daily for 14 days to confirm the whitening effect. The results showed a significant improvement in whitening effect when the toner containing Capsule 2 was applied. Figure 5 ).

[0102] [Example 5] Skin barrier improvement effect of microcapsules containing linker peptides (capsules 3-3)

[0103] [Example 5-1] Effect of enhancing the expression of keratin 1 and keratin 5

[0104] To observe the skin barrier improvement effect of capsule 3 with peptide-linked peptides, an increased expression of keratin was observed. 10 μM of microcapsules with and without peptide-linked peptides were treated on the capsule surface to confirm the expression levels of these factors. The results showed that, when using capsule 3, the expression levels of keratin 1 and keratin 5 were approximately twice as high as those of capsules without peptide-linked peptides (in order of...). Figure 6a , 6b ).

[0105] [Example 5-2] Enhanced effect on filaggrin synthesis

[0106] The filaggrin synthesis effect was confirmed by treating the capsules using the same method as in Example 5-1. As a result, when using capsule 3, approximately 5-fold filaggrin expression was confirmed compared to capsules without peptide linkage. Figure 6c ).

[0107] [Example 6] Evaluation Test of Skin Barrier Strengthening Effect

[0108] Twenty women aged 35-55 without skin diseases underwent a nutrient cream containing 20% ​​Capsule 3 applied evenly to their entire face twice daily for 14 days. Dermal density and skin thickness were assessed. Results showed that the application of the nutrient cream containing Capsule 3 significantly improved dermal density and skin thickness, thus confirming an improvement in the skin barrier. Figure 7 ).

[0109] [Example 7] Effect differences based on peptide density

[0110] For the experimental groups listed in Table 2, the experiments in Examples 3 to 6 were performed in the same manner. When capsules 1-3, 2-3, and 3-3 were contained (density 2 peptides / μm),... 2 The effect of (time) is 10, and the results of each experimental group are represented by the relative values ​​of capsules 1-3, 2-3, and 3-3.

[0111] Table 3 records the experimental results corresponding to the experiment in Example 3, Table 4 records the experimental results corresponding to Example 4, and Table 5 records the experimental results corresponding to Example 6.

[0112] Table 3

[0113]

[0114] Table 4

[0115]

[0116]

[0117] Table 5

[0118]

[0119] The results showed that the peptide density exceeded 0.1–10 peptides / µm. 2 When applied to a small area, the effect on improving skin condition is minimal.

[0120] [Dosage Form Example]

[0121] [Example of dosage form 1] Toner (for highlighting)

[0122] Table 6

[0123]

[0124]

[0125] [Dosage Form Example 2] Ampoules (for aging improvement) Table 7

[0126]

[0127]

[0128] [Dosage Form Example 3] Serum (for aging improvement) Table 8

[0129]

[0130] [Dosage Form Example 4] Eye Cream (for Aging Improvement) Table 9

[0131]

[0132]

[0133] [Dosage Form Example 5] Emulsion (for elasticity) Table 10

[0134]

[0135] [Dosage Form Example 6] Nourishing Cream (for Elasticity) Table 11

[0136]

[0137]

[0138] Sequence List Free Text

[0139] Serial number 1 (Ala-Lys-Ser-Thr) is the sequence of a peptide that targets fibroblasts. The peptide in serial number 1 can bind to the fibroblast growth factor receptor.

[0140] Sequence number 2 (Glu-Gly-His-Lys-Ile-Phe-Pro-Ser-Trp-Tyr) is the sequence of a peptide that targets melanocytes. The peptide in sequence number 2 can bind to the melanocortin receptor.

[0141] Serial number 3 (Ala-Asp-Gly-Ser-Pro) is the sequence of a peptide that targets keratinocytes. The peptide in serial number 3 can bind to integrin receptors, especially the β1 family of integrin receptors.

Claims

1. A peptide having cell receptor binding energy, characterized in that, The peptide consists of the sequence number 3.

2. A microcapsule, characterized in that, The peptide according to claim 1 is attached to a surface.

3. The microcapsule according to claim 2, characterized in that, The peptides are based on the total cross-sectional area of ​​the microcapsules, with a concentration of 0.1–10 peptides / μm. 2 The density includes.

4. The microcapsule according to claim 2, characterized in that, The microcapsules also contain the active ingredients sealed inside the capsule. The active ingredient comprises one or more of the following: amino acids; plant-derived proteins or their hydrolysates; yeast ferments, their solutions or their filtrates; and plant extracts.

5. The microcapsule according to claim 4, characterized in that, The plant-derived protein includes lupin protein. The yeast includes Pichia pastoris.

6. The microcapsule according to claim 4, characterized in that, The amino acids, based on the total weight of the active ingredients, can be contained in a percentage of 0.00001 to 0.1 by weight. The plant-derived protein or its hydrolysate, yeast ferment, its solution or its filtrate, and plant extracts are contained in 0.0001 to 30% by weight of the total weight of the active ingredients.

7. A cosmetic composition, characterized in that, It comprises the microcapsule as described in claim 2.

8. The cosmetic composition according to claim 7, characterized in that, The cosmetic composition is for moisturizing and skin barrier strengthening.

Images